Mismatch Repair Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
CONCLUSIONS: Over one-fourth of dMMR rectal tumors treated with neoadjuvant chemotherapy exhibited disease progression. Conversely, dMMR rectal tumors were sensitive to chemoradiation. MMR status should be performed upfront in all locally advanced rectal tumors with careful monitoring for response on neoadjuvant chemotherapy and genetic testing for LS in dMMR rectal cancer patients.
PMID: 32144135 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, Yaeger R, Segal NH, Reidy-Lagunes DL, Varghese AM, Markowitz A, Wu C, Szeglin B, Sauvé CG, Salo-Mullen E, Tran C, Patel Z, Krishnan A, Tkachuk K, Nash GM, Guillem J, Paty PB, Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Eloxatin | Gastroschisis Repair | Genetics | HNPCC | Lynch Syndrome | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Rectal Cancers